Porton Advanced proudly announces its CDMO support for Tasly Pharmaceutical Co., Ltd.'s innovative CAR-T therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This marks a significant advancement in the treatment of recurrent glioblastoma (GBM), a highly aggressive and deadly brain cancer.

As the exclusive CDMO partner for this program, Porton Advanced provided comprehensive process development and manufacturing services covering plasmid production, lentiviral vectors, and final CAR-T cell products. The company successfully delivered dozens of batches of clinical-grade investigational products for Investigator-Initiated Trials (IITs), with all batches passing quality control on the first attempt.